Mikhail V. Blagosklonny, MD PhD Professor Oncology
@Blagosklonny
Followers
22K
Following
5K
Media
37
Statuses
8K
Rapamycin for immortality. Hyperfunction theory of aging. Near-curing of incurable cancer Editor-in-Chief: https://t.co/vOLFBqirGU & https://t.co/ivXaGJvXZo
Boston USA
Joined January 2017
Before I die (too late discovered cure of any cancer?) 😎. Published 10 min ago https://t.co/gSNuGPZdcv
39
26
198
Dear Misha, When I was a child, I told people you were a scientist in Antarctica studying penguins. I truly believed it. When I was in 7th grade, my teacher asked us to write an essay about a famous scientist. I thought of you immediately. Then I knew a little bit more about
18
9
89
Listen to an #audio recording of a #pressrelease about this #editorial: "Targeted cancer therapy: the initial high concentration may slow down the selection for resistance." https://t.co/8qnFlEs13L
#lungcancer #cancer #aging #soundcloud #podcast #openaccess #peerreviewed #press
2
6
10
Watch an #agingshort #video about this #editorial by @blagosklonny: "Targeted cancer therapy: The initial high concentration may slow down the selection for resistance." @RoswellPark DOI: https://t.co/8yUJEib3gP
#aging #lungcancer #cancer #brain #metastases #research #openaccess
0
5
13
0
5
11
#PaperSpotlight: On July 28, @Blagosklonny from @RoswellPark published a new #editorial in Aging, entitled, “Targeted cancer therapy: The initial high concentration may slow down the selection for resistance." #PressRelease: https://t.co/z5md4fwFBw
#lungcancer #cancer #research
aging-us.com
Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance."Listen to an audio version of this press releaseBUFFALO, NY-...
0
5
14
Sometimes, cancer does not respond to anti-cancer therapies. To put it another way, anti-cancer therapies, sometimes, just do not stop the progression (growth) of cancer. However, the Nobel Prize-winning treatment with Immune Checkpoint Inhibitors (ICI), known as Immunotherapy,
7
7
50
Elon Musk agrees: "good". Thank you, all of you 😘
1/3 July 31, 2024 . Second attempt 😎
1
0
36
1
2
13
1/3 July 31, 2024 . Second attempt 😎
4
4
95
My own experience with quinacrine - @weldeiry
@JDWinkler1956 @MarmorsteinLab
https://t.co/J7GvWBE8yY
#Cancer #CancerResearch #ClinicalTrial #OncoDaily #Oncology
0
2
21
A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation https://t.co/kBxPFbkkXy
0
1
6
A druggable cascade links methionine metabolism to epigenomic reprogramming in squamous cell carcinoma https://t.co/uq7MXwtLoK
0
1
9
@weldeiry We would like to inform you that your post has been successfully published on Oncodaily. Thank you for sharing. https://t.co/J7GvWBDAJq
oncodaily.com
Wafik S. El-Deiry: My own experience with quinacrine / cancer, Cancer research, clinical study, clinical trial, FDA, NCI, NIH, OncoDaily, Oncology, Wafik S.
0
4
9
New law will aid R.I. cancer researchers, patients | Cumberland | https://t.co/dbucUuvzp4
valleybreeze.com
PROVIDENCE – A new law sponsored by Deputy Majority Whip Mia A. Ackerman and Sen. Samuel D. Zurier will allow patients and medical researchers access to vital national data and
0
4
7
Great presentations today at #eldeirylab meeting @BrownUCancer @BrownMedicine @BrownUniversity #LegorretaCancerCenter by visiting summer @MSMEDU medical student Brian Baker, and visiting high school students Harshita Ganga from Ohio and Tanush Talekar from Pennsylvania. Also
0
3
7
In 2015 we treated this pt (refractory basal call ca, metastatic liver, bones, brain— in wheelchair) with nivolumab High TMB, PDL1 amp In CR 8.5+ years @AaronGoodman33
3
6
52